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Background: Sufficient evidence is lacking to draw final conclusions on the efficiency of medical and psychological
treatments of traumatized refugees with PTSD. The pharmacological treatments of choice today for post-traumatic
stress disorder are antidepressants from the subgroup selective serotonin reuptake inhibitors, especially Sertraline.
The evidence for the use of selective serotonin reuptake inhibitors in the treatment of complex post-traumatic
stress disorder in traumatized refugees is very limited. Venlafaxine is a dual-action antidepressant that works on
several pathways in the brain. It influences areas in the brain which are responsible for the enhanced anxiety and
hyper-arousal experienced by traumatized refugees and which some studies have found to be enlarged among
patients suffering from post-traumatic stress disorder.
Design: This study will include approximately 150 patients, randomized into two different groups treated with
either Sertraline or Venlafaxine. Patients in both groups will receive the same manual-based cognitive behavioral
therapy, which has been especially adapted to this group of patients. The treatment period will be 6 to 7 months.
The trial endpoints will be post-traumatic stress disorder and depressive symptoms and social functioning, all
measured on validated ratings scales. Furthermore the study will examine the relation between a psycho-social
resources and treatment outcome based on 15 different possible outcome predictors.
Discussion: This study is expected to bring forward new knowledge on treatment and clinical evaluation of
traumatized refugees and the results are expected to be used in reference programs and clinical guidelines.
Trial registration: ClinicalTrials.gov NCT01569685
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The treatment of traumatized refugees is one of the least
researched areas within the field of psychiatry. Most
research on post-traumatic stress disorder (PTSD) and
other psychiatric conditions related to traumatic stress
have been carried out on victims of other kinds of trau-
matic experience such as rape, traffic accidents or trauma
related to war. There are reasons to believe that mental
symptoms experienced after trauma relates to the type* Correspondence: charlotte.sonne@regionh.dk
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reproduction in any medium, provided the orand intensity of the trauma. Most traumatic events (traffic
accidents, robberies, natural disasters, et cetera) are of lim-
ited duration. However, many refugees experience more or
less constant or repeated trauma for months or even years,
such as periods with daily exposure to torture during a
long imprisonment. The current PTSD diagnosis often
does not fully capture the severe psychological harm that
occurs with such prolonged trauma. People such as refu-
gees experiencing long-lasting trauma often report add-
itional symptoms alongside formal PTSD symptoms, such
as alterations in emotional control and dissociative symp-
toms. Although not a formal diagnosis in either the Diag-
nostic and Statistical Manual of Mental Disorders (DSM)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nostic system, this is often referred to as complex PTSD
by clinicians and researchers within the field.
Apart from a history of repeated trauma in their coun-
try of origin, the process of forced immigration experi-
enced by refugees is often traumatic and dramatically
impacts the lives of individuals and families [1,2]. It also
tears apart the social structures that are often very im-
portant to people from highly collectively minded soci-
eties. Furthermore, the ways of understanding mental
health problems often differ from the country of origin
to the receiving country. With this in mind, the research
results from studies conducted on other patient popula-
tions cannot simply be transferred to traumatized refu-
gees. It is therefore problematic that the three available
Cochrane analyses of PTSD have only been able to iden-
tify very few studies of traumatized refugees [3-5].
The Danish Medical Technology Report (MTV report),
The treatment and rehabilitation of PTSD inclusive trau-
matized refugees [6], concluded that antidepressants from
the subgroup of selective serotonin reuptake inhibitors
(SSRIs), among these the drug Sertraline, are currently
the drugs of choice for the treatment of PTSD. However
the report also concluded that SSRIs are inadequate as
a treatment for complex PTSD. Some antidepressants
from the subgroup of dual-action products, among these
Venlafaxine, have shown promising results in clinical case
reports [7] but have not been investigated thoroughly in
randomized studies on traumatized refugees. Studies of
other groups of PTSD patients conclude that both short-
term and long-term Venlafaxine treatment is effective in
PTSD [8,9]. Although the exact pathophysiology of PTSD
still remains to be fully understood, the brain’s noradren-
ergic pathways are recognized to be involved. Venlafaxine
acts on both serotonin and norepinephrine pathways in
many areas in the brain. Among other structures it is be-
lieved to play a role in the regulation of the amygdala,
which is currently held at least partly responsible for the
enhanced anxiety and hyper arousal experienced by trau-
matized refugees. This gives us reason to believe that this
drug could provide greater relief of cluster D PTSD symp-
toms in particular.
A Cochrane review from 2010 of combined pharmaco-
logical and psychological treatment of PTSD included
only four studies, all conducted on a very limited num-
ber of patients [4]. The authors concluded ‘Further re-
search into the clinical management of PTSD is required
including large trials that use (i) reliable and clinically
meaningful outcome measurements such as remission
of PTSD, (ii) consistent measures of PTSD symptoms
and (iii) functional outcomes, including those related to
social and occupational function’. Furthermore, the au-
thors called for studies of homogeneous populations
such as traumatized refugees.The latest Cochrane review, as well as the MTV report
mentioned above, consider social functioning to be an im-
portant issue, which could potentially be a trial endpoint
on the same level as symptoms ratings [4,6]. Related to
this issue is the current lack of understanding of the re-
lationship between psychosocial resources and treatment
outcome.
Objectives
The objectives are to: 1) examine differences in the treat-
ment outcome of patients treated with Venlafaxine and
Sertraline respectively; 2) study the relationship between
changes in symptoms in PTSD /depression and changes
in social functioning from baseline to post treatment
evaluation; 3) investigate if pre-treatment ratings of pa-
tient resources correlate with the actual outcome of the
treatment for the individual patient.
Methods
The study is a randomized clinical trial aiming to include
approximately 200 traumatized refugees of which a mini-
mum of 150 are estimated to complete the trial in accord-
ance with the protocol. Patients are randomized into two
groups treated with either Sertraline or Venlafaxine in
combination with manual-based cognitive therapy, as de-
scribed below. The treatment period is 6 to 7 months.
Treatment outcome is evaluated in two ways, through
self-ratings and blinded observer-ratings. Patients com-
plete self-ratings on three occasions during the study;
these are at the pre-treatment consultation (baseline), be-
tween phase 1 and 2 (please see below), and at the end of
the treatment period. Blinded observer-ratings are carried
out by a team of trained medical students who do not
know to which intervention group the patient has been
randomized. These ratings are carried out at the begin-
ning and at the end of the treatment period. The rating
scales are described in detail in the outcome section
below.
Participants
The study is being carried out at the Psychiatric Trauma
Clinic for Refugees (PTF), which is part of the Psychi-
atric Center Ballerup, situated in the Capital Region of
Denmark. The different effects of two medical treatments
in combination with psychotherapy are being studied on a
relatively homogenous group of adult (≥ 18 years of age)
traumatized refugees who are referred to the PTF during
the study period. Social functioning will be included as
one of the trial endpoints and psychosocial predictors and
their relation to treatment outcome will be analyzed.
The study will ultimately include approximately 200
patients over a period of 15 months. About 150 patients
are expected to complete the study (based on previ-
ous studies at the PTF in a similar group of patients).
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practitioner (GP) or by a referring doctor in a specialist
unit. If it seems likely that the patient belongs to the tar-
get group of the clinic, he or she will be invited to a pre-
treatment consultation.
Inclusion criteria
The inclusion criteria are as follows: patients must be
referred to PTF between 1 April 2012 and 31 June 2013; ≥
18 years of age; have symptoms of PTSD in accordance
with the ICD-10 research criteria; have had psychological
trauma in the past; be motivated to undergo treatment;
provide written informed consent.
Exclusion criteria
Patients will be excluded if they are suffering from ser-
ious psychotic disorder (defined by ICD-10 diagnosis
F2x and F30.1-F30.9); are currently abusing drugs or al-
cohol (ICD-10 F.1×.24-F1×.26); are in need of admission
to a psychiatric hospital; do not give written informed
consent, or are pregnant, breast feeding or plan to be-
come pregnant during the project period.
If the patient fulfils the inclusion criteria, and is not
excluded by the exclusion criteria, the patient is included
and randomized to one of two intervention groups:
Treatment groups
Group V1 is assigned to treatment with Venlafaxine and
manualised psychotherapy developed to fit the target
group of the clinic. Group S2 is assigned to treatment
with Sertraline and manualised psychotherapy developed
to fit the target group of the clinic. In both groups treat-
ment is planned to last between 6 and 7 months. TheFigure 1 Treatment and data collection.treatment and the ratings are shown in Figure 1. The
different parts of the intervention are described in detail
below.
The intervention
The intervention consists of a combination of medical,
psychological and psychosocial treatment and is divided
into two phases. During phase 1 (the first 2 months) the
patient only has consultations with the doctor and re-
ceives no psychological treatment. During phase 2 (the
last 4 months) the patient has sessions with both the
doctor and the psychologist as described below. The pa-
tient meets with the social counsellor at least twice dur-
ing the study period. If extra consultations are agreed,
these are registered in the patient record (for example, if
there are medical or psychosocial problems that need
immediate attention).
Medical intervention
Each patient is offered 10 sessions with one of the medical
doctors at the PTF. Sessions are scheduled to take place
weekly during phase 1 and monthly during phase 2. Dur-
ing these sessions the medical treatment of the ran-
domized group is initiated and monitored. If the patient
suffers from extensive sleeping problems, Mianserine (10
to 30 mg) is given additionally in both groups. If at all
possible, patients are taken off all other kinds of psycho-
pharmacological treatment. In small doses Mianserine is
believed to act primarily on sleep disturbances, not on
symptoms of depression. Furthermore, Mianserine is giv-
en for the same indication in both groups of patients.
Mianserine should not affect our ability to analyze differ-
ences in treatment response for Sertraline and Venlafaxine
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lieve that Mianserine interacts differently with either of
the two drugs being compared in this trial.
In addition to the medical treatment, the patients re-
ceive psycho-education on topics such as symptoms of
PTSD and depression; the rationale for treatment; healthy
lifestyle, including exercise and proper diet; breathing and
relaxation exercises; sleep disturbances, and chronic pain.
Twelve different one-page handouts are available at PTF
on a range of these topics (in five different languages).
They are given to the patients to take home when a topic
has been discussed during a treatment session. The pa-
tient and the doctor together decide the relevant topic for
each session.
The medical and psycho-educational treatment is thor-
oughly described in a treatment manual followed by all
doctors. The main topic of each session is registered in
the patient record together with side effects of the treat-
ment and any social problems that the patient has. Fur-
thermore, a brief psychiatric evaluation is carried out by
the doctor and noted using a tick-box system developed
at PTF and used in previous studies.
Psychological intervention
Each patient is offered one introductory session and six-
teen therapeutic sessions with a psychologist. The in-
troduction session is in phase 1, before or right at the
beginning of the treatment period. The remaining ses-
sions take place during phase 2.
All therapy is based on the same manual, which is
primarily based on cognitive therapy with elements of
trauma-focused therapy, acceptance commitment ther-
apy (ACT) and mindfulness. The methods have been
adapted to this patient group on the basis of the avail-
able literature and on experience of the three manuals
previously used at the clinic.
After each session the therapist fills in a methodology
scheme in the patient record, thereby registering the
methods that were used during the session and whether
the patient had completed planned homework. All psy-
chologists regularly attend manual supervision sessions
to ensure that therapy is in accordance with the manual
and to avoid too much inter-therapist variation.
Psycho-social intervention
All patients are offered at least two appointments with a
social counsellor during the project period: one at the
beginning and one towards the end of the treatment.
During these sessions patients are asked to complete
two self-ratings that are related to social functioning and
network; these are further described below. After the
first session the social counsellor writes a letter to the
patient’s contact at the social services office describing
the social problems that the patient might have. Allcontacts to external parties, including the patient’s rela-
tives, are registered in the patient record.
Group lectures
Group lectures are offered to all patients once a month.
Three different lectures are offered, one on each of the
following topics: the structure of the Danish municipal
administration and social services; advice on financial
debt and the tax system, and citizenship and possibilities
for support and social activities. As lectures are offered
every month in a fixed rotation the patients have two
possibilities to attend each of the different lectures dur-
ing a 6-month period.
Outcome
Data collection combines self-ratings and observer-ratings.
Patients are asked to fill in self-ratings three times: at their
first appointment at PTF (baseline), immediately before
they start on phase 2, and at the end of the treatment
period. Patients and doctors are not treatment-blinded,
but a team of specially trained intervention-blinded med-
ical students are carrying out Hamilton anxiety and de-
pression ratings at baseline and at completion of the
treatment. Interpreters assist the patients during both rat-
ings and treatment sessions when needed. All the rating
scales used in the study are validated and have previously
been used in different cultural settings. At PTF they are
available in five different languages.Primary outcome measure
The Harvard trauma questionnaire (HTQ) [10] is a self-
administered rating scale used to monitor the severity of
PTSD in different patient groups, among these, groups
of traumatized refugees. It is internationally recognized
and validated in several different languages. The first 16
questions in the HTQ part IV (symptoms) have been
chosen to monitor PTSD symptoms, as they cover all
PTSD symptoms in both DSM-IV and ICD-10.
Secondary outcome measures
The Hopkins symptom check list-25 (HSCL-25) [11] is a
self-administered rating scale used to monitor the se-
verity of anxiety and depression symptoms. It consists of
25 questions, 10 about anxiety symptoms and 15 about
depression symptoms. The social adjustment scale self-
report (SAS-SR) short version [12] is a self-administered
rating scale used to monitor social functioning during
treatment. It is a shorter version of a 54-question rating
scale. The short form used in this study consists of 24
questions. The Hamilton depression and anxiety ratings
scales (HAM D+A) [13] are observer-administered rat-
ing scales based on a semi-structured interview. They
have been used for many years in different areas of
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iety symptoms.
Other psychometric instruments used in the study
The following instruments areused: the WHO-5, a five-
item self-administered rating scale used to monitor life
quality in different groups of psychiatric patients; the
somatisation items of Symptom Check List-90 (SCL-90), a
self-administered rating scale broadly used in the psychi-
atric field, using the part of the scale that monitors somatic
complaints; pain in four different body areas measured
using a visual analogue scale (VAS), a self-administered
rating scale used to monitor pain in four different body
areas, namely the head, arms, legs and neck/back; the
Sheehan disability scale (SDS), a self-administered rating
scale comprising three different VAS scales used to meas-
ure three different areas of functioning, namely family life,
work and social networks; global assessment of function-
ing (GAF), an observer-administered rating scale used to
evaluate symptoms and functioning level in adults. InFigure 2 Rating of psychosocial resources in patients at the Psychiatrclinical settings the GAF is used to monitor treatment ef-
fect in many different groups of psychiatric patients; goal
attainment scaling (GAS), which is used to make the indi-
vidual patient state his/her own measures for successful
treatment outcome in a way that makes it possible to use
it for treatment evaluation, and finally, the crisis support
scale (CSS), a seven-item self-rating scale used to monitor
the social support experienced after a traumatic event in
different groups of PTSD patients.
Psycho-social resources and relation to treatment
outcome
If a patient agrees to participate in the treatment program
a ratings table (Figure 2) is completed in accordance with
a manual explaining the rating of each item, to secure
inter-rater reliability. This is done during the first session
with the patient, which is scheduled before the actual
treatment or at the beginning of the treatment program.
The doctor completes the first five questions, the psych-
ologist completes the next five, and the last five questionsic Trauma Clinic for Refugees.
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score, the patients are divided into three groups: high,
moderate or limited psycho-social resources. These groups
are not to be confused with the treatment groups.
The purpose of this part of the study is to investigate
associations between psychosocial resources and treat-
ment outcome. Consequently, after completed treatment,
the patients are again divided into three groups, but this
time in accordance with outcome (high, moderate or lim-
ited) measured by the primary outcome measure of the
study. The psychosocial resource categorization is then
compared with the outcome categorization in order to
analyze whether there is a relation between psychosocial
resources and the ability to benefit from the treatment.
Furthermore, the individual rating items are analyzed to
identify the strongest outcome predictors.
Randomization
The randomization list is made by the Biostatistics De-
partment at the University of Copenhagen, while the
randomization of the individual patient is carried out by
a group of secretaries in a division of the Psychiatric
Center in Ballerup that is independent of the PTF. Be-
fore randomization, stratification is made by gender and
baseline HTQ score.
Data analysis
Sample size and power calculations
If the included 150 patients are divided into two groups
of equal size, the power to detect a group difference of
half of 1 SD on the rating scales will be 86%, while the
power to detect a difference of 1 SD will be close to
100%. Differences of less than half of 1 SD are consid-
ered to be of marginal interest from a clinical point of
view.
Statistical analysis
For analysis of objective 1, the outcome variables are the
baseline, second and third ratings in the primary and
secondary outcome measures. With two intervention
groups and three ratings, the design of the study may be
described as a 2 × 3 factorial design with repeated mea-
sures of the last factor. Analysis of variance (ANOVA)
with repeated measures of one factor can be used to
analyze this design, but multi-level analysis will be more
efficient if there are missing observations on one or
more of the three ratings. In these analyses the main ef-
fect of the rating factor represent changes during the
course of therapy, but the main focus is the interaction
between the group and rating factor, corresponding to
group differences in patterns of mean ratings. If differ-
ence scores are calculated between the three ratings,
group differences in differences scores correspond to
this interaction. Group differences in multiple differencevariables can be analyzed by multivariate analysis of vari-
ance (MANOVA), while single difference variables (for
example, between the third rating and the baseline score)
can be tested with a t-test for independent groups. Ad-
justment for the effect of baseline values on outcome var-
iables and background factors (such as gender and age)
can be done using analysis of covariance (ANCOVA)/linear
regression, including multi-level models. Intention-to-treat
analyses will be carried out alongside completer analyses.
For analysis of objective 2, the relationship between
changes in social functioning and changes in symptoms
can be calculated by bivariate or partial correlations, if
adjustments are made for baseline or background factors
as described above. For objective 3, from the baseline
predictor table patients are divided into three groups
according to the predicted treatment outcome and using
relevant statistical methods. This categorization is com-
pared with a categorization based on the actual treatment
outcome. The degree of concordance can be evaluated
with kappa coefficients or correlation coefficients based
on the uncategorized ordinal measures of predicted and
actual treatment outcome.Ethics
The trial protocol has been approved by The Ethics
Committee of the Capital Region of Denmark, the
Danish Medicines Agency and the Danish Data Protec-
tion Agency. The project recognizes the Helsinki II Dec-
laration. Participation in the project is voluntary and
requires written, informed consent. Patients who do not
wish to participate in the project still have the right to
receive equal treatment at the PTF. Randomization is
considered ethical, as current evidence cannot clarify
whether one of the treatments offered to the patients is
better than the other.
Publications
Three publications are planned after the conclusion of
the data collection to describe 1) the effect of Sertraline
versus Venlafaxine on trauma-related psychiatric disorder
in refugees; 2) changes in social functioning in relation
to PTSD and depression symptoms during a six-month
treatment program for traumatized refugees, and 3) the
relationship between psychosocial resources and treat-
ment outcome in traumatized refugees.
Trial status
Patient inclusion in this trial started on 1 April 2012 and
is scheduled to continue until 31 June 2013.
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